Company intelligence / Profile preview

OmicsWay

California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

OmicsWay Corp. has developed a computational algorithm that predicts the efficacy of targeted cancer therapies by analyzing individual tumor transcriptomes and signaling pathway activation. The approach enables ranking potential efficacies of various targeted drugs for personalized oncology treatment. Two clinical trials are associated with the company's technology, focusing on identifying molecular biomarkers for cancer therapy response.

Therapeutic areas: Oncology
Modalities: Computational platform (not a therapeutic developer; focuses on computational prediction for targeted therapies)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on OmicsWay.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OmicsWay.

Explore the full profile